SOM230
Sponsors
Dana-Farber Cancer Institute, University of Pittsburgh, Novartis Pharmaceuticals, Lynn Feun
Conditions
Carcinoid TumorCastration Resistant Prostate CancerCluster Headache - Episodic and ChronicDumping SyndromeHepatocellular CarcinomaMultiple MyelomaMultiple Myeloma in RelapseNeuroendocrine Tumor
Phase 1
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
CompletedNCT00804336
Start: 2008-10-31End: 2015-04-30Updated: 2016-10-19
A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers
CompletedNCT01578928
Start: 2012-05-31End: 2014-05-31Updated: 2020-12-21
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
CompletedNCT01590199
Start: 2012-05-18End: 2018-09-11Updated: 2019-04-16
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
CompletedNCT01646684
Start: 2013-03-08End: 2018-11-13Updated: 2020-12-21
Phase 2
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
WithdrawnNCT01329289
Start: 2011-12-31End: 2012-02-29Updated: 2016-02-12
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
CompletedNCT01637272
Start: 2013-01-08End: 2015-08-07Updated: 2017-05-10
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
CompletedNCT01639352
Start: 2012-07-31End: 2017-02-28Updated: 2017-07-12
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
TerminatedNCT02619617
Start: 2016-10-31End: 2018-09-25Updated: 2021-01-05